Acorn Bioventures

Acorn Bioventures is a New York-based investment firm founded in 2017 that invests across stages in private and small-cap publicly traded biotechnology companies developing novel medicines. The firm also invests in and partners with specialty pharmaceutical and medical device companies, extending its coverage beyond pure-play therapeutics into broader medical products. Its stated orientation is towards connecting institutional capital with businesses advancing treatments for patients.

Its approach spans the private and public markets rather than concentrating on a single financing stage, including early-stage ventures. Alongside capital, the firm provides strategic partnerships to portfolio companies - a structure common among healthcare-focused managers that combine investment with operating input into drug-development programmes.

Nine portfolio companies are named across the firm's holdings. These include Freeline, Neuron23, Bicara Therapeutics, Cogent Biosciences, Acrivon Therapeutics, Eliem Therapeutics and Q32 Bio in therapeutics, and CG Oncology and OnKure Therapeutics in oncology. The technical domains covered include therapeutics, oncology, drug development, specialty pharmaceuticals and medical devices.

Acorn Bioventures operates from New York, United States.